Therapeutic targeting SPI1 in combination with erastin promotes ferroptosis in ccRCC
Wei Xue, Zhengqi Wu, Jixin Li, Peng Jin, Yuze Zhu, Zhiyuan Li, Zhijiao Wang, Zhenhua Li, Xiang Fei · 2025
Read Therapeutic targeting SPI1 in combination with erastin promotes ferroptosis in ccRCC by Wei Xue, Zhengqi Wu, Jixin Li, Peng Jin, Yuze Zhu, Zhiyuan Li, Zhijiao Wang, Zhenhua Li, Xiang Fei (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12708875.txt.
Description
Wei Xue and eight co-authors target a gene switch to help kill kidney cancer cells in a 2025 paper. The commonest kidney cancer type often resists treatment. A switch called SPI1 runs high in these tumors and marks a poor outlook.
The team shows SPI1 holds back a rust-like cell death called ferroptosis, which drugs like erastin can trigger. Silencing SPI1 let erastin kill far better. Tracing the wiring, SPI1 uses a partner protein to muffle a gene the death pathway needs, shielding the cell. Blocking that partner worked like silencing SPI1. The authors propose hitting SPI1 alongside erastin as a fresh line of attack.
Catalog record
| CREATOR | Wei Xue, Zhengqi Wu, Jixin Li, Peng Jin, Yuze Zhu, Zhiyuan Li, Zhijiao Wang, Zhenhua Li, Xiang Fei |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |